Detection of Endometrial Cancer Through Risk Modelling
Key facts
- Where
- Vancouver, CanadaSee the site
Where in Canada
- VGH Research PavilionVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of British Columbia
- Trial code
- NCT06268626
- Record updated
- 16 April 2026
- Original description
The study goal is to investigate a non-invasive approach to predict endometrial cancer (EC) risk, better understand disease progression and identify opportunities for intervention.Read full original descriptionShow less
Non-Invasive Strategies for Early Detection of Uterine Cancer in Patients With Abnormal Uterine Bleeding
The study goal is to investigate a non-invasive approach to predict endometrial cancer (EC) risk, better understand disease progression and identify opportunities for intervention.
This two-part case-cohort prospective study will recruit patients whose abnormal uterine bleeding is being evaluated via endometrial biopsy. Participants will complete an online health questionnaire, and a subset will be invited to self-collect vaginal samples for sequencing.
Selected sequenced participants will be invited for longitudinal monitoring (questionnaires, wearable fitness tracker) and an additional vaginal self-collection to identify persistent genetic mutations or microbiome alterations 6-8 months later.
Inclusion: Study Part A:; 40 years and older; Experiencing unexplained abnormal uterine bleeding (i.e., not from IUD, etc.); Have an intact uterus; Referred for an endometrial biopsy; Study Part B/Longitudinal monitoring:; Those selected for sequencing (from Part A) and who retained their uterus.
Exclusion: Started hormone therapy (HRT, birth control, IUD) in the past year (with the exception of tamoxifen); Endometrial sampling, pelvic radiation, or vaginal infection (vaginosis, yeast) in the past 3 months; Study Part A:; Intercourse, vaginal product use, or douching in the past 48 hours; Study Part B/Longitudinal monitoring:; Same as Study Part A; EC or EIN, or anyone who is recommended a hysterectomy.